BioVie announces formation of Corporate Advisory Board

BioVie (BIVI) announced the formation of its Corporate Advisory Board – a coalition of seven powerhouse leaders in science, technology, medicine and capital markets who bring unparalleled expertise and decades of personal business success across biotechnology, neuroscience, venture capital, M&A, business and communications. The overarching mission of BioVie’s Corporate Advisory Board is to support ongoing clinical development efforts, inform business strategy and enhance stakeholder engagement. Importantly, each advisor shares a deep-rooted personal connection to the neuroinflammatory conditions that the Company is hoping to address with its investigational drug candidate, bezisterim. Their collective expertise will help the Company in a myriad of ways, including securing the capital needed for robust clinical development and educating key stakeholders about the critical roles that neuroinflammation and the associated insulin resistance play in the onset and progression of neuroinflammatory diseases, including Alzheimer’s disease, Parkinson’s disease and long COVID. Ugochi Owo, Chair- Serial Entrepreneur & Operator; Zaldy Tan, MD, MPH – Director, Cedars-Sinai Memory & Aging Program; Kush Saxena – Global Fintech Veteran Former CEO, GetNet, Former SVP MasterCard; Tim Gardner, PhD – Associate Professor of Neuroengineering, University of Oregon Co-Founder, Neuralink; Justina Omokhua – Senior Vice President, Parkwood Entertainment Former Global Head of Content Strategy, Apple; Gregory Nguyen – Technologist Private Markets Strategist; Casey Woo – CEO, Operators Guild Seven-Time High-Growth CFO/COO.